Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection

NCT07600775 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT07600775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07600775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
January 19, 2027
Enrollment
14 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv pre-exposure prophylaxis, human immunodeficiency virus (hiv)